| Name | Title | Contact Details |
|---|---|---|
Douglas Beck |
Chief Financial Officer | Profile |
Douglas Larson |
Chief Financial Officer | Profile |
FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
TruSpine is a medical device company focused on entering the $10.2 billion (US) per annum spinal device market. The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices. The Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine). These unique devices represent a paradigm shift in spinal fixation, by providing exceptional stabilization while not altering the bony anatomy such as screws, staples or other devices which currently dominate the spinal market. The TruSpine philosophy and mantra is one of preserving nature`s design, and as such, the devices have been designed to be safer, faster and easier to implant. The potential cost savings to patients, insurers and surgeons can be significant. The technology is minimally intrusive, minimally invasive and reversable. The first product to market will be Cervi-LOK™, and will be the first posterior cervical stabilisation device in the world which fully preserves the boney anatomy of the spine. TruSpine has a phased product development strategy, and is planning to commence initial product marketing between late 2020 to early 2021. The overall aim is to establish the TruSpine products as the go-to solutions for the spinal stabilisation market. In addition to the three flagship platform products currently under development, the company also has a pipeline of additional and complementary spinal products.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC`s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amann Girrbach America is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.